fluphenazine has been researched along with Anochlesia in 43 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fourteen di- and tripeptide analogues of MIF, Pro-Leu-Gly-NH2, have been synthesized and assayed for inhibition of oxotremorine-induced tremor." | 7.66 | Tripeptide analogues of melanocyte-stimulating hormone release-inhibiting hormone (Pro-Leu-Gly-NH2) as inhibitors of oxotremorine-induced tremor. ( Björkman, S; Castensson, S; Sievertsson, H, 1979) |
| "Fourteen di- and tripeptide analogues of MIF, Pro-Leu-Gly-NH2, have been synthesized and assayed for inhibition of oxotremorine-induced tremor." | 3.66 | Tripeptide analogues of melanocyte-stimulating hormone release-inhibiting hormone (Pro-Leu-Gly-NH2) as inhibitors of oxotremorine-induced tremor. ( Björkman, S; Castensson, S; Sievertsson, H, 1979) |
| " The compound antagonized amphetamine-induced stereotyped behavior in rats, amphetamine toxicity in aggregated mice and apomorphine-induced emesis in dogs." | 3.65 | The behavioral pharmacology of butaclamol hydrochloride (AY-23,028), a new potent neuroleptic drug. ( Herr, F; Voith, K, 1975) |
| "By contrast, catalepsy induced by a single injection of haloperidol lasted only approximately 2 days, and tolerance developed to its effects after long-term treatment." | 1.30 | D2 dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of D2 dopamine-mediated behaviors without causing Up-regulation of D2 dopamine receptors. ( Davidkova, G; Morabito, M; Weiss, B; Zhang, SP; Zhou, LW, 1998) |
| "Prominent catalepsy, otherwise consistently seen in the mice treated with haloperidol (0." | 1.30 | Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats. ( Buljat, G; Dodig, G; Jelovac, N; Marovic, A; Miklic, P; Mise, S; Perovic, D; Petek, M; Prkacin, I; Rucman, R; Seiwerth, S; Sikiric, P; Turkovic, B, 1999) |
| "Animals were tested for catalepsy response on a horizontal bar test while concurrently collecting dialysis samples." | 1.29 | Single preexposure to fluphenazine produces persisting behavioral sensitization accompanied by tolerance to fluphenazine-induced striatal dopamine overflow in rats. ( Meil, W; See, RE, 1994) |
| "1." | 1.28 | Blockade of both D-1 and D-2 dopamine receptors may induce catalepsy in mice. ( Habibi-Moini, S; Zarrindast, MR, 1991) |
| "The neuroleptic-induced catalepsy was reversed by the classical anti-parkinsonian agent L-DOPA and by agents that function through dopamine systems such as d- and methamphetamine and the direct D2 receptor agonist quinpirole." | 1.28 | Neuroleptic-induced catalepsy as a model of Parkinson's disease. I. Effect of dopaminergic agents. ( Close, SP; Elliott, PJ; Hayes, AG; Marriott, AS; Walsh, DM, 1990) |
| " SHPGE2, PGE2, and C did not cause catalepsy and did not show statistically significant dose-response antagonism of rotational behavior at less than toxic doses." | 1.26 | Neuropharmacological and behavioral evaluation of prostaglandin E2 and 11-thiol-11-desoxy prostaglandin E2 in the mouse and rat. ( Bloss, JL; Singer, GH, 1978) |
| "The reduction of fluphenazine-induced catalepsy produced by 5-HT depletion within the substantia nigra supports the concept of a controlling influence of 5-HT on nigro-striatal DA function." | 1.26 | A study of the sites of interaction between dopamine and 5-hydroxytryptamine for the production of fluphenazine-induced catalepsy. ( Carter, CJ; Pycock, CJ, 1978) |
| "The pilocarpine-catalepsy was abolished by atropine, promethazine and nomifensine and unaffected by tricyclic antidepressants." | 1.26 | On the anticataleptic action of cyproheptadine. ( Klimek, V; Maj, J; Rawlów, A; Sarnek, J, 1976) |
| "PCA had no influence on catalepsy induced by neuroleptics from the group of butyrophenones, potentiated the cataleptic action of reserpine in the dose of 5 mg/kg, and suppressed catalepsy induced by reserpine in the dose of 10 mg/kg." | 1.25 | The effect of 5-hydroxytrytamine synthesis inhibitors on neuroleptic-induced catalepsy in rats. ( Baran, L; Sarnek, J, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 33 (76.74) | 18.7374 |
| 1990's | 9 (20.93) | 18.2507 |
| 2000's | 1 (2.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Voith, K | 3 |
| Bruderlein, FT | 1 |
| Humber, LG | 1 |
| Bossle, PC | 1 |
| Ferguson, CP | 1 |
| Sultan, WE | 1 |
| Lennox, WJ | 1 |
| Dudley, GE | 1 |
| Rea, TH | 1 |
| Miller, JI | 1 |
| Nudelman, A | 1 |
| Gil-Ad, I | 1 |
| Shpaisman, N | 1 |
| Terasenko, I | 1 |
| Ron, H | 1 |
| Savitsky, K | 1 |
| Geffen, Y | 1 |
| Weizman, A | 1 |
| Rephaeli, A | 1 |
| BOISSIER, JR | 1 |
| SIMON, P | 1 |
| Irwin, S | 1 |
| Stille, G | 2 |
| Björkman, S | 2 |
| Lewander, T | 1 |
| Zetterström, T | 1 |
| Bacopoulos, NG | 1 |
| Yamada, K | 2 |
| Furukawa, T | 2 |
| Qin, ZH | 1 |
| Zhou, LW | 2 |
| Zhang, SP | 2 |
| Wang, Y | 1 |
| Weiss, B | 2 |
| Meil, W | 1 |
| See, RE | 1 |
| Davidkova, G | 1 |
| Morabito, M | 1 |
| Jelovac, N | 1 |
| Sikiric, P | 1 |
| Rucman, R | 1 |
| Petek, M | 1 |
| Marovic, A | 1 |
| Perovic, D | 1 |
| Seiwerth, S | 1 |
| Mise, S | 1 |
| Turkovic, B | 1 |
| Dodig, G | 1 |
| Miklic, P | 1 |
| Buljat, G | 1 |
| Prkacin, I | 1 |
| Maj, J | 4 |
| Rogóz, Z | 1 |
| Skuza, G | 1 |
| Costall, B | 6 |
| Fortune, DH | 1 |
| Naylor, RJ | 6 |
| Castensson, S | 1 |
| Sievertsson, H | 1 |
| Bloss, JL | 1 |
| Singer, GH | 1 |
| Hui, SC | 1 |
| Carter, CJ | 1 |
| Pycock, CJ | 1 |
| Chen, PC | 1 |
| Bowers, MB | 1 |
| Bowers, SM | 1 |
| Sarnek, J | 4 |
| Klimek, V | 1 |
| Rawlów, A | 1 |
| Herr, F | 1 |
| Baran, L | 2 |
| Zarrindast, MR | 1 |
| Habibi-Moini, S | 1 |
| Elliott, PJ | 2 |
| Close, SP | 2 |
| Walsh, DM | 2 |
| Hayes, AG | 2 |
| Marriott, AS | 2 |
| Domeney, AM | 1 |
| Kelly, ME | 1 |
| Tomkins, DM | 1 |
| Yamamoto, T | 1 |
| Ueki, S | 1 |
| Antelman, SM | 1 |
| Kocan, D | 1 |
| Edwards, DJ | 1 |
| Knopf, S | 1 |
| Perel, JM | 1 |
| Stiller, R | 1 |
| Julou, L | 1 |
| Bourat, G | 1 |
| Ducrot, R | 1 |
| Fournel, J | 1 |
| Garret, C | 1 |
| Kapturkiewicz, Z | 1 |
| Lauener, H | 1 |
| Chandra, O | 1 |
| Bernard, J | 1 |
| Matussek, N | 1 |
| Moller Nielsen, I | 1 |
| Fjalland, B | 1 |
| Pedersen, V | 1 |
| Nymark, M | 1 |
| Sowińska, H | 1 |
| Uno, M | 1 |
| Niemegeers, CJ | 1 |
| Verbruggen, FJ | 1 |
| Janssen, PA | 1 |
43 other studies available for fluphenazine and Anochlesia
| Article | Year |
|---|---|
Neuroleptics related to butaclamol. Synthesis and some psychopharmacological effects of a series of 3-aryl analogues.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Butaclamol; Catalepsy; Conditioning, Psychologica | 1978 |
Synthesis and biological activity of new 2-substituted analogs of fluphenazine.
Topics: Animals; Catalepsy; Fluphenazine; Humans; Male; Mice; Motor Activity; Rats; Structure-Activity Relat | 1976 |
A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Biological Availability; Catalepsy; Dextroamphe | 2008 |
[EXPERIMENTAL EQUIVALENTS OF THE NEUROLOGIC SYNDROME OF NEUROLEPTICS].
Topics: Antipsychotic Agents; Catalepsy; Catatonia; Chlorpromazine; Fluphenazine; Haloperidol; Humans; Neuro | 1964 |
Considerations for the pre-clinical evaluation of new psychiatric drugs: a case study with phenothiazine-like tranquilizers.
Topics: Aggression; Animals; Ataxia; Behavior, Animal; Catalepsy; Emotions; Extrapyramidal Tracts; Fear; Flu | 1966 |
[Arousal inhibiting and catalepsy in neuroleptic drugs].
Topics: Animals; Arousal; Catalepsy; Chlorpromazine; Chlorprothixene; Fluphenazine; Haloperidol; Humans; Met | 1966 |
MIF (Pro-Leu-Gly-NH2): failure to affect oxotremorine effects in mice and rats as well as fluphenazine catalepsy or amphetamine hyperactivity in rats.
Topics: Amphetamine; Animals; Catalepsy; Fluphenazine; Humans; Male; Mice; Motor Activity; MSH Release-Inhib | 1980 |
Antipsychotic drug effects on dopamine and serotonin receptors: in vitro binding and in vivo turnover studies.
Topics: Animals; Antipsychotic Agents; Brain; Butaclamol; Catalepsy; Dopamine; Fluphenazine; Haloperidol; Hu | 1981 |
behavior of rats and mice administered active metabolites of fluphenazine, 7-hydroxy-fluphenazine and fluphenazine-sulfoxide.
Topics: Animals; Behavior, Animal; Body Temperature; Catalepsy; Exploratory Behavior; Fluphenazine; Humans; | 1980 |
Catalepsy produced by long-acting neuroleptics, fluphenazine enanthate and fluphenazine decanoate, in mice.
Topics: Aminooxyacetic Acid; Animals; Antiparkinson Agents; Catalepsy; Delayed-Action Preparations; Drug Syn | 1982 |
D2 dopamine receptor antisense oligodeoxynucleotide inhibits the synthesis of a functional pool of D2 dopamine receptors.
Topics: Animals; Behavior, Animal; Catalepsy; Corpus Striatum; Fluphenazine; Male; Mice; Oligonucleotides, A | 1995 |
Single preexposure to fluphenazine produces persisting behavioral sensitization accompanied by tolerance to fluphenazine-induced striatal dopamine overflow in rats.
Topics: Animals; Behavior, Animal; Catalepsy; Dopamine; Dose-Response Relationship, Drug; Drug Tolerance; Ex | 1994 |
D2 dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of D2 dopamine-mediated behaviors without causing Up-regulation of D2 dopamine receptors.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; | 1998 |
Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats.
Topics: Animals; Anti-Ulcer Agents; Antipsychotic Agents; Catalepsy; Clozapine; Dopamine Antagonists; Dose-R | 1999 |
The anticataleptic effect of 7-OH-DPAT: are dopamine D3 receptors involved?
Topics: Animals; Antipsychotic Agents; Brain Chemistry; Catalepsy; Dextroamphetamine; Dopamine Agents; Dopam | 1999 |
Synthetic MIF analogues. Part II: Dopa potentiation and fluphenazine antagonism.
Topics: Animals; Behavior, Animal; Catalepsy; Dihydroxyphenylalanine; Drug Synergism; Fluphenazine; Humans; | 1977 |
Involvement of mesolimbic and extrapyramidal nuclei in the motor depressant action of narcotic drugs.
Topics: Animals; Catalepsy; Caudate Nucleus; Dopamine Antagonists; Extrapyramidal Tracts; Fluphenazine; Huma | 1978 |
Tripeptide analogues of melanocyte-stimulating hormone release-inhibiting hormone (Pro-Leu-Gly-NH2) as inhibitors of oxotremorine-induced tremor.
Topics: Animals; Catalepsy; Chemical Phenomena; Chemistry; Fluphenazine; Humans; Male; Mice; Molecular Confo | 1979 |
Neuropharmacological and behavioral evaluation of prostaglandin E2 and 11-thiol-11-desoxy prostaglandin E2 in the mouse and rat.
Topics: Animals; Avoidance Learning; Behavior, Animal; Catalepsy; Clozapine; Dextroamphetamine; Fluphenazine | 1978 |
Correlation between multitest and single test catalepsy assessment.
Topics: Animals; Catalepsy; Fluphenazine; Haloperidol; Humans; Male; Rats; Time Factors | 1978 |
A study of the sites of interaction between dopamine and 5-hydroxytryptamine for the production of fluphenazine-induced catalepsy.
Topics: Animals; Behavior, Animal; Brain Chemistry; Catalepsy; Dopamine; Fluphenazine; Humans; Male; Rats; S | 1978 |
[Pharmacological studies of long-acting phenothiazines with particular reference to fluphenazine decanoate (author's transl)].
Topics: Animals; Apomorphine; Blood Pressure; Body Temperature; Brain; Catalepsy; Catecholamines; Electrocar | 1978 |
Catalepsy, DOPAC, and acetylcholine during chronic fluphenazine administration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholine; Animals; Brain; Catalepsy; Caudate Nucleus; Cerebral | 1978 |
On the anticataleptic action of cyproheptadine.
Topics: Animals; Atropine; Catalepsy; Clomipramine; Cyproheptadine; Desipramine; Female; Fluphenazine; Human | 1976 |
The behavioral pharmacology of butaclamol hydrochloride (AY-23,028), a new potent neuroleptic drug.
Topics: Amphetamine; Animals; Apomorphine; Avoidance Learning; Behavior, Animal; Catalepsy; Chlorpromazine; | 1975 |
Detection of the nueroleptic properties of clozapine, sulpiride and thioridazine.
Topics: Animals; Apomorphine; Behavior, Animal; Catalepsy; Clozapine; Dextroamphetamine; Dibenzazepines; Dos | 1975 |
The effect of 5-hydroxytrytamine synthesis inhibitors on neuroleptic-induced catalepsy in rats.
Topics: Amphetamines; Catalepsy; Fluphenazine; Humans; p-Chloroamphetamine; Pimozide; Reserpine; Serotonin; | 1975 |
Blockade of both D-1 and D-2 dopamine receptors may induce catalepsy in mice.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Catalepsy; Dopami | 1991 |
Neuroleptic-induced catalepsy as a model of Parkinson's disease. I. Effect of dopaminergic agents.
Topics: Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dopamine; Dose-Response Relationsh | 1990 |
Neuroleptic-induced catalepsy as a model of Parkinson's disease. II. Effect of glutamate antagonists.
Topics: Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dizocilpine Maleate; Fluphenazine; | 1990 |
Actions of ORG 5222 as a novel psychotropic agent.
Topics: Amphetamines; Animals; Behavior, Animal; Callitrichinae; Catalepsy; Dibenzocycloheptenes; Dibenzoxep | 1990 |
Behavioral and electroencephalographic effects of a depot type neuroleptic fluphenazine decanoate, in rats.
Topics: Acoustic Stimulation; Agonistic Behavior; Animals; Avoidance Learning; Behavior, Animal; Catalepsy; | 1989 |
Behavioral effects of a single neuroleptic treatment grow with the passage of time.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Catalepsy; Corpus Striatum; Dopamine; Fluphenazine; | 1986 |
Pharmacological study of pipotiazine (19.366 R.P.) and its undecylenic (19.551 R.P.) and palmitic (19.552 R.P.) esters.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Catalepsy; Dogs; Esters; Fluphenazine; Guin | 1973 |
The nucleus amygdaloideus centralis and neuroleptic activity in the rat.
Topics: Amygdala; Animals; Behavior; Benzoates; Butyrophenones; Catalepsy; Dextroamphetamine; Dibenzazepines | 1974 |
The effect of L-dopa on neuroleptic-induced catalepsy.
Topics: Animals; Catalepsy; Chlorpromazine; Dihydroxyphenylalanine; Fenclonine; Fluphenazine; Humans; Male; | 1972 |
[Effect of neuroleptic agents in the chronic pharmacological experiment].
Topics: Animals; Apomorphine; Behavior, Animal; Catalepsy; Corpus Striatum; Dibenzoxazepines; Drug Tolerance | 1974 |
Long-term trial of fluphenazine decanoate and flupenthixol decanoate for cataleptic activity and effect on motor activity in rats.
Topics: Animals; Catalepsy; Circadian Rhythm; Darkness; Depression, Chemical; Dose-Response Relationship, Dr | 1974 |
Mesolimbic involvement with behavioural effects indicating antipsychotic activity.
Topics: Animals; Behavior, Animal; Catalepsy; Dextroamphetamine; Dibenzothiazepines; Dose-Response Relations | 1974 |
Pharmacology of neuroleptics upon repeated administration.
Topics: Amphetamine; Animals; Apomorphine; Avoidance Learning; Catalepsy; Cross Reactions; Dose-Response Rel | 1974 |
Pharmacological effects of 1,3-dimethyl-5-aminoadamantane, a new adamantane derivative.
Topics: Amantadine; Animals; Apomorphine; Blood Pressure; Body Temperature; Brain Chemistry; Catalepsy; Chlo | 1974 |
[Follow-up studies of schizophrenia].
Topics: Adult; Catalepsy; Catatonia; Chlorpromazine; Chronic Disease; Convulsive Therapy; Depersonalization; | 1971 |
The influence of various neuroleptic drugs on noise escape response in rats.
Topics: Animals; Antidepressive Agents; Avoidance Learning; Benperidol; Blepharoptosis; Butyrophenones; Cata | 1970 |